Merck & Company, Inc. (MRK) Shares Bought by Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc. grew its stake in Merck & Company, Inc. (NYSE:MRK) by 29.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,277 shares of the company’s stock after buying an additional 8,101 shares during the period. Pinnacle Financial Partners Inc.’s holdings in Merck & were worth $2,261,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of MRK. Waldron LP boosted its holdings in shares of Merck & by 54.3% in the 1st quarter. Waldron LP now owns 17,248 shares of the company’s stock valued at $1,087,000 after buying an additional 6,071 shares in the last quarter. Brouwer & Janachowski LLC acquired a new position in shares of Merck & in the 1st quarter valued at $250,000. B & T Capital Management DBA Alpha Capital Management boosted its holdings in shares of Merck & by 4.8% in the 1st quarter. B & T Capital Management DBA Alpha Capital Management now owns 37,084 shares of the company’s stock valued at $2,356,000 after buying an additional 1,696 shares in the last quarter. Headinvest LLC boosted its holdings in shares of Merck & by 2.2% in the 1st quarter. Headinvest LLC now owns 26,530 shares of the company’s stock valued at $1,686,000 after buying an additional 560 shares in the last quarter. Finally, Sit Investment Associates Inc. boosted its holdings in shares of Merck & by 3.1% in the 1st quarter. Sit Investment Associates Inc. now owns 409,453 shares of the company’s stock valued at $26,017,000 after buying an additional 12,350 shares in the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/11/01/merck-company-inc-mrk-shares-bought-by-pinnacle-financial-partners-inc.html.
Merck & Company, Inc. (MRK) opened at 55.09 on Wednesday. The stock has a market cap of $150.25 billion, a P/E ratio of 29.83 and a beta of 0.80. The firm’s 50-day moving average is $63.71 and its 200-day moving average is $63.55. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80.
Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.07 earnings per share. On average, equities analysts forecast that Merck & Company, Inc. will post $3.92 earnings per share for the current fiscal year.
A number of analysts recently weighed in on MRK shares. Cowen and Company reiterated a “hold” rating and set a $70.00 price target on shares of Merck & in a research note on Friday, September 1st. J P Morgan Chase & Co set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a research note on Sunday. Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “sell” rating and set a $55.00 price target on shares of Merck & in a research note on Friday, October 20th. Finally, Barclays PLC cut shares of Merck & from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $72.00 to $62.00 in a research note on Monday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. Merck & has an average rating of “Hold” and a consensus target price of $67.07.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.